Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
CA 2266341 A1 · Owner: The General Hospital Corporation · Inventors: Reed, Guy L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction thrombosis or , stroke in a patient which comprises administering an alpha-2-antiplasminbinding molecule capable of preventing inibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministering an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 19, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 19, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 19, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.